Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    South Korea retail sales climb 5.6% in March

    April 29, 2026

    China’s Yangtze River Pharmaceutical Group Expands Global Footprint as Quality Drives Growth

    April 29, 2026

    Powering Low-Carbon Mining: Sungrow Unveils Mining Microgrid Power Solutions White Paper

    April 28, 2026
    • Home
    • Contact Us
    Suez PostSuez Post
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Suez PostSuez Post
    Home » OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position
    ACCESS Newswire

    OKRA.ai, an Envision Pharma Group Company, Appoints Dr. Yahya Anvar to Senior Leadership Position

    June 15, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    PHILADELPHIA, PA / ACCESSWIRE / June 15, 2023 / OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

    Envision Pharma Group, Thursday, June 15, 2023, Press release picture

    “I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space,” shares Meg Heim, CEO of Envision Pharma Group. “His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness.”

    Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai’s portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

    Anvar shares, “It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients’ outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I’m so excited to be working with the Envision team to transform the industry as we know it.”

    Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, “It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights.”

    About Envision Pharma Group

    Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

    Contact Information:

    Colleen Carter
    Associate Director, Communications, Office of CEO
    colleen.carter@envisionpharma.com
    1 (508) 505 8856

    SOURCE: Envision Pharma Group

    .

    Related Posts

    Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance

    April 22, 2026

    Datavault AI Announces Upcoming Listing of Meme Coin Portfolio and Institutional RWA Token Suite on the Biconomy Exchange

    April 13, 2026

    Datavault AI Inc. (NASDAQ: DVLT) Announces $750 Million in Tokenization Contracts Signed in Q1 2026, Generating $77 Million in Associated Fees

    April 8, 2026

    Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026

    April 2, 2026

    Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform

    April 1, 2026

    Safe Staffing Requires New Models of Care, Not Just More Clinicians, Says Global Taskforce

    March 30, 2026
    Recent News

    South Korea retail sales climb 5.6% in March

    April 29, 2026

    UAE and Mauritania presidents deepen bilateral ties

    April 27, 2026

    UAE India dialogue turns to security and energy

    April 27, 2026

    UAE mediation helps Russia and Ukraine swap 386 captives

    April 25, 2026

    Syria gets US$225 million World Bank water health aid

    April 24, 2026

    Bilateral ties and regional security reviewed in UAE Dutch talks

    April 24, 2026

    UAE President and Italy defence chief discuss security

    April 23, 2026

    Dnata invests A$32 million in Western Sydney cargo hub

    April 23, 2026
    © 2026 Suez Post | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.